26 results
Thumbnail

D3.48 - The delabeling of beta-lactam allergy does not change the antibiotic prescribing profile or alerts in Primary Care. The experience of a General Hospital

Thumbnail

D3.53 - A retrospective audit of NSAID hypersensitivity in children and young people in a tertiary paediatric allergy centre

Thumbnail

D3.55 - Synthetic folic acid allergy

Thumbnail

D3.47 - Implementing Penicillin Delabelling in an Inpatient setting

Thumbnail

D3.49 - Clinical significance and safety of provocation test for drug allergy diagnosis in outpatient unit: A real world observational study

Thumbnail

D3.50 - Penicillin-allergic labelled patients with a PEN-FAST score of 0 could safely be de-labelled by non-allergists

Thumbnail

D3.51 - Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists

Thumbnail

D3.54 - Hypersensitivity reactions during therapy with platinum compounds and taxanes – who can benefit from consulting an allergist?

Thumbnail

D3.56 - Relevant Aspects in the Investigation of Hypersensitivity Reactions to Non-Beta-Lactam Antibiotics

Thumbnail

D3.57 - Isoniazid-Induced Lupus in a Filipino Female: A Case Report

Thumbnail

D3.58 - Drug-Induced Enterocolitis Syndrome (DIES) Associated to Amoxicillin and Amoxicillin-Clavulanic Acid: A Growing Concern at a Tertiary Hospital

Thumbnail

D3.59 - Insights from Drug Provocation Testing in Quinolone Allergy

Thumbnail

D3.60 - Iodinated Contrast Media During Acute DRESS: A Hidden Risk for Future Drug Hypersensitivity?

Thumbnail

D3.62 - Beta-Lactam Hypersensitivity: 5-year characterization of patients evaluated at the University of Chile Clinical Hospital

Thumbnail

D3.63 - 5 Year Follow Up: Unveiling True Beta-Lactam Immediate Hypersensitivity in the University of Chile Clinical Hospital

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis